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Abstract 
The administration of l‑arginine hydrochloride has been used for testing pituitary secretion in humans, and as an 
experimental model for induction of acute pancreatitis in rats and mice. Whereas in the first case, the administration 
of the amino acid is associated with hiperkalemia, in the model of acute pancreatitis no data are available on pos‑
sible changes in potassium homeostasis. The present study shows that the acute administration to mice of l‑arginine 
hydrochloride or other cationic amino acids almost duplicate plasma potassium levels. This effect was associated 
to a marked decrease of tissue potassium in both pancreas and liver. No changes were found in other tissues. These 
changes cannot be ascribed to the large load of chloride ions, since similar effects were produced when l‑ornithine 
aspartate was administered. The changes in potassium levels were dependent on the dose. The displacement of 
intracellular potassium from the liver and pancreas to the extracellular compartment appears to be dependent on the 
entry of the cationic amino acid, since the administration of an equivalent dose of alfa‑difluoromethyl ornithine HCl 
(DFMO), a non physiological analog of l‑ornithine, which is poorly taken by the tissues in comparison with the physi‑
ological cationic amino acids, did not produce any change in potassium levels in pancreas and liver. The analyses of 
the expression of cationic amino acid transporters (CAT) suggest that the CAT‑2 transporter may be implicated in the 
potassium/cationic amino acid interchange in liver and pancreas. The possible physiological or pathological relevance 
of these findings is discussed.
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Background
Potassium is the principal intracellular cation in the 
body. Under normal conditions approximately 98  % of 
total body potassium is present in the intracellular space, 
while 2 % is in the extracellular fluid (Forbes and Lewis 
1956; Pierson et al. 1974). It plays then an important role 
in maintaining the electrochemical gradient across mem-
branes (Bia and DeFronzo 1981; Young and McDonough 
2009), which is critical for the functions of many cells, 
particularly those of excitable tissues, such as nerve and 
muscle (Palmer 2015). Furthermore, potassium ions 
participate in regulating the secretion of many hor-
mones, such as aldosterone (Bassett et al. 2004), insulin 
(Dluhy et al. 1972; Hiatt et al. 1972; DeFronzo et al. 1978), 
growth hormone (Dluhy et al. 1972), sex hormones and 
gonadotropins (Sánchez-Capelo et al. 1993; Tejada et al. 
1998).
Different studies revealed that the efflux of potassium 
from cells to the extracellular compartment was associ-
ated with the administration of l-arginine and other cati-
onic amino acids both in intact animals (Dickerman and 
Walker 1964), including humans (Merimee et  al. 1965; 
Alberti et  al. 1967; Merimee et  al. 1967; Massara et  al. 
1979), and also in isolated rat muscle (Levinsky et  al. 
1962). Infusion of l-arginine hydrochloride has been 
used to stimulate growth hormone secretion (Knof et al. 
1965; Merimee et al. 1965, 1967). Although this test may 
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be considered nonhazardous when renal function is nor-
mal, different reports have revealed that the treatment 
may induce dangerous increases of serum potassium 
concentration in uremic and diabetic patients (Hertz and 
Richardson 1972; Bushinsky and Gennari 1978; Massara 
et al. 1979). Hyperkalemia after cationic amino acid infu-
sion has also been observed in patients receiving infusion 
of l-arginine and l-lysine for renal protection, during 
peptide radiotherapy of neuroendocrine tumours (Rol-
leman et  al. 2003; Barone et  al. 2004; Giovacchini et  al. 
2011). In all these cases the tissular origin of the elevation 
of plasma potassium concentration was not analyzed. In 
addition, the administration of large doses of l-arginine 
to mice and rats has been used as a model to induce 
experimental pancreatitis (Tani et al. 1990; Takács et al. 
2002; Hegyi et al. 2004; Dawra et al. 2006; Hyvönen et al. 
2006; Kang et  al. 2014). To our knowledge, there is no 
data available about a possible alteration of body potas-
sium homeostasis produced by this treatment.
The aim of the present study was to investigate the lev-
els of potassium in plasma and in different organs after 
administration of l-arginine and other cationic amino 
acids, at the doses used to induce acute experimental 
pancreatitis in mice, in order to know which tissue types 
drive out potassium to the extracellular compartment 
after administration of the cationic amino acids.
Methods
Chemicals
l-Arginine hydrochloride, l-lysine hydrochloride, l-orni-
thine hydrochloride, l-ornithine aspartate, l-glucose and 
primers were purchased from Sigma Aldrich. Difluoro-
methyl ornithine (DFMO) was kindly supplied by Dr Pat-
rick M Woster (Wayne State University).
Animals and treatments
Adult male Swiss CD1 mice were purchased from the 
University of Murcia Laboratory Animal Facilities. All 
the animals were housed in standard box cages in a cli-
mate controlled room with an ambient temperature of 
22  ±  1  °C and 12:12  h light–dark cycle. Animals were 
fed standard laboratory chow, given water ad libitum and 
randomly assigned to control or experimental groups. 
All animal procedures were compliant with the national 
and European guidelines of animal welfare and approved 
by the Bioethics Committee of the University of Murcia 
(548/2011).
Sterile solutions of cationic amino acids (l-arginine, 
l-lysine, l-ornithine) and DFMO were prepared in nor-
mal saline, and the pH was adjusted to 7.0. They were 
administered intraperitoneally to non fasted mice at 
a dose of 4  g/kg. l-ornithine was also administered a 
doses of 2 and 3  g/kg. Animals were returned to the 
cages and allowed free access to food and water. After 
1  h hour a second dose of the corresponding amino 
acid was administered. Control animals received 
sham injections of saline alone. Two hours after the 
last injection, animals were anesthetized with sodium 
pentobarbital and blood samples were collected by 
cardiac puncture. Animals were then killed by cervical 
dislocation, and tissues were quickly removed, weighed 
and processed.
Potassium content analysis of plasma and tissues
Plasma was obtained by centrifugation of blood samples 
at 7000×g for 5  min. Tissues and plasma were homog-
enized in 0.3  M trichloroacetic acid (1:10  wt/vol) using 
a tissue homogenizer (Polytron), and the extracts were 
centrifuged at 7000×g for 10 min. Potassium content was 
determined using flame photometry.
Real‑time RT‑PCR analysis
Total RNA was extracted from tissues using the TRIzol 
Plus RNA Purif Kit (Invitrogen) according to the manu-
facturer’s instruction. First-strand cDNA was gener-
ated from 5 μg of total RNA using (dT)18 as primer and 
MMLV-Reverse Transcriptase (Sigma). Real-time RT-
PCR was carried out using a SYBR Green® PCR Master 
Mix and a 7500 Real-Time instrument (Applied Biosys-
tems). Different sets of primers and cDNA were used 
and the fluorescence data were collected and analyzed by 
means of 7500 SDS software (Applied Biosystems). The 
following primers were used: β-actin (forward, 5′-GATT 
ACTGCTCTGGCTCCTAGCA-3′; reverse, 5′-GCTCA 
GGAGGAGCAA TGATCTT-3′); CAT1 (forward, 5′-TC 
ACTGGCTGGAACCTGATTCT-3′; reverse, 5′-CTCTC 
CGATGGGCTTGCCTA-3′); CAT2A (forward, 5′-GCTC 
CCTCTG CGCCTTATC-3′; reverse, 5′-TCTAAACAG 
TAAGCCATCCCGG-3′); CAT2B (forward, 5′-TCGGC 
AGGCTCCCTCT-3′; reverse, 5′-CACTGCACCCG ACG 
ACA-3′). The expression level of each gene was normal-
ized against the housekeeping gene β-actin.
Statistic analysis
Results are expressed as the mean ± SEM. Statically anal-
ysis was done by applying unpaired two-tailed Students t 
test with significance assigned to P values <0.05
Results
The results presented in Fig.  1 show that the adminis-
tration of cationic amino acids l-arginine HCl, l-lysine 
HCl or l-ornithine HCl (4  g/kg, i.p. twice in 1  h inter-
val) produced a very significant rise in plasma potassium 
levels when measured 2  h after the last administration. 
Page 3 of 10Cremades et al. SpringerPlus  (2016) 5:616 
The three cationic amino acids tested showed a simi-
lar increase in potassium plasma levels, reaching values 
close to 10 mEq/L.
Figure  2 shows that the administration of l-arginine 
HCl, l-lysine HCl or l-ornithine induced a very signifi-
cant decrease of potassium levels in pancreas (panel A) 
and liver (panel B). The decrease of the potassium con-
tent in the pancreas (55–60  %) was higher than that 
found in the liver (37–46 %).
Table 1 shows the potassium levels in other different tis-
sues after the administration of the cationic amino acids 
l-arginine HCl, l-lysine HCl or l-ornithine HCl to mice. 
In contrast with the big changes found in potassium lev-
els in plasma, pancreas and liver, the treatment only pro-
duced small potassium changes in the brain, heart, spleen, 
skeletal muscle and testis. In the kidney, lysine and orni-
thine but not arginine, produced a slight but significant 
decrease in potassium levels (10  % for lysine and 23  % 
for ornithine). Conversely, all these amino acids pro-
duced a small but significant rise in potassium brain levels 
(~10 %). In the heart, lysine and ornithine but not arginine 
elicited a small but significant increase in potassium levels 
(10–15  %). A smaller increase in the potassium content 
was also found in the testis. In spleen and skeletal muscle, 
no changes in potassium levels were observed.
In order to test the possible influence of chloride ions 
on the potassium changes associated to the administra-
tion of the cationic amino acids under their hydrochlo-
ride forms, we compared the effect of administering 
equimolecular doses of either l-ornithine HCl or l-orni-
thine aspartate forms to mice on plasma and tissue 
potassium levels. As can be seen from Fig. 3, the adminis-
tration of l-ornithine aspartate to mice produced marked 
decreases of potassium concentration in both pancreas 
and liver, comparable to those caused by ornithine HCl. 
However, as shown in Fig.  3c, the increase in plasma 
potassium levels after the administration of the aspartate 
form was significantly smaller than that found for orni-
thine HCl. In addition, the aspartate salt form of l-orni-
thine produced a significant increase in brain potassium 
levels (11 %) and a significant decrease of potassium lev-
els in the kidney (23  %), with no significant changes in 
heart, spleen and skeletal muscle (Table 2). These effects 
were similar, except for the heart, to those found after the 



































Fig. 1 Effects of the administration of cationic amino acids to mice 
on plasma levels of potassium. l‑Arginine HCl, l‑lysine HCl and 
l‑ornithine HCl (4 g/kg) were given intraperitoneally (two injections, 
1 h apart) and plasma potassium was determined 2 h after the last 
injection. Results are given as mean ± SE from a minimum of six ani‑























































Fig. 2 Effects of cationic amino acids administration to mice on 
pancreas (a) and liver (b) potassium levels. l‑Arginine HCl, l‑lysine 
HCl and l‑ornithine HCl (4 g/kg) were given intraperitoneally (two 
injections, 1 h apart) and tissue potassium was determined 2 h after 
the last injection. Results are given as mean ± SE from a minimum 
of six animals per group. Statistical significance: (**) P < 0.001, (***) 
P < 0.0001 versus control
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To corroborate that the decrease in potassium content 
in pancreas and liver was associated with the uptake of 
the cationic amino acids, the ornithine analog alfa-difluo-
romethylornithine (DFMO, eflornithine), which is poorly 
taken up by mammalian cells most likely by passive dif-
fusion (Grove et  al. 1981; Erwin and Pegg 1982), was 
administered to mice (4 g/kg, i.p. twice in 1 h interval). 
No significant changes in potassium levels in liver and 
pancreas were observed (Fig. 4).
The effects of the administration of different doses of 
l-ornithine HCl (2, 3, and 4 g/kg, i.p. twice in 1 h inter-
val) on plasma, liver and pancreas levels of potassium are 
shown in Fig.  5. l-Ornithine at the dose of 2  g/kg pro-
duced a significant decrease of potassium levels in pan-
creas (13 %) and in the liver (31 %), with no changes in 
plasma potassium concentrations (Fig. 5; panel a). How-
ever, higher doses (3 and 4  g/kg) induced a significant 
increased in potassium plasma concentrations accom-
panied with a very significant decrease in pancreas (28 % 
for 3 g/kg and 60 % for 4 g/kg) and liver (43 % for 3 g/kg 
and 50 % for 4 g/kg) potassium levels (Fig. 5).
The determine whether the effects produced by the 
cationic amino acids on potassium exchange were com-
parable to those produced by other nutrients efficiently 
captured by liver and pancreas, d-glucose (at the dose of 
4 g/kg i.p. twice at 1 h interval) was administered to mice. 
Figure  6 shows that this sugar did not produce any sig-
nificant change in potassium levels, either in plasma or 
the tissues analyzed.
Since the effect of cationic amino acid administra-
tion on tissue potassium levels mainly affected liver and 
Table 1 Effects of  the administration to  mice of  cationic 
amino acids on  potassium levels in  brain, heart, spleen, 
skeletal muscle, kidney and testis
l-Arginine HCl, l-lysine HCl and l-ornithine HCl (4 g/kg) were given 
intraperitoneally (two injections, 1 h apart) and tissue potassium was 
determined 2 h after the last injection. Results are given as mean ± SE from a 
minimum of six animals per group, and are expressed as µmol/g
ND not determined
Statistical significance: (*) P < 0.05 versus control; (**) P < 0.01 versus control; 
(***) P < 0.001 versus control
Control Arginine HCl Lysine HCl Ornithine HCl
Brain 95.05 ± 1.4 103.5 ± 1.3** 110.4 ± 1.9*** 108.6 ± 1.5***
Heart 75.60 ± 1.6 77.50 ± 3.0 87.60 ± 2.9* 86.20 ± 3.9*
Spleen 111.8 ± 1.7 103.6 ± 2.8 105.1 ± 2.6 113.3 ± 3.0
Muscle 97.05 ± 2.2 101.1 ± 2.9 102.3 ± 3.2 99.20 ± 2.0
Kidney 70.20 ± 2.2 68.80 ± 2.2 63.20 ± 1.1* 54.60 ± 2.5*








































































Fig. 3 Effects of ornithine HCl and ornithine‑asparte administration 
to mice on plasma (a), pancreas (b), and liver (c) potassium levels. 
Amino acids (4 g/kg) were given intraperitoneally (two injections, 1 h 
apart) and tissue potassium was determined 2 h after the last injec‑
tion. Results are given as mean ± SE from a minimum of six animals. 
Statistical significance: (***) P < 0.0001 versus control. (++) P < 0.001 
versus l‑ornithine HCl
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pancreas, the expression levels of the different cationic 
amino acid transporters was studied by RT-PCR in these 
tissues. Figure 7a shows that l-ornithine administration 
produced a significant increase in liver CAT-2A, the only 
cationic amino acid transporter detected in liver. In pan-
creas, the three transporters CAT 1, CAT-2A and CAT-
2B were detected. In this tissue, the administration of 
l-ornithine showed a tendency to increase the levels of 
mRNA of the three transporters, although it was statisti-
cally non-significant.
Discussion
The results of the present study indicate that the admin-
istration of high doses of cationic amino acids to mice 
produce a marked increase in potassium plasma lev-
els. This is in agreement with previous observations 
that showed that in humans, the infusion of arginine 
monohydrochloride, a practice used to test pituitary 
function (Merimee et al. 1965, 1967), was associated with 
increases in plasma potassium concentration (Alberti 
Table 2 Effects of  ornithine HCl or ornithine-asparte 
administration to  mice on  the potassium levels in  brain, 
heart, spleen, skeletal muscle, and kidney
l-Ornithine HCl (4 g/kg) or l-ornithine aspartate (6 g/kg) were given 
intraperitoneally (two injections, 1 h apart) to mice and tissue potassium was 
determined 2 h after the last injection. Results are given as mean ± SE from six 
animals and are expressed as µmol/g
Statistical significance: (*) P < 0.05 versus control; (**) P < 0.001 versus control
Control Ornithine HCl Ornithine aspartate
Brain 93.14 ± 1.1 108.1 ± 1.3*** 104.0 ± 1.9***
Heart 73.25 ± 1.4 84.36 ± 3.4* 78.14 ± 2.7
Spleen 112.9 ± 2.6 112.6 ± 2.0 106.0 ± 3.0
Muscle 95.14 ± 3.3 104.3 ± 3.8 104.6 ± 5.1
















Fig. 4 Effects of the administration of α‑difluoromethylornithine HCl 
(DFMO) to mice on pancreas and liver potassium levels. DFMO (4 g/
kg) was given intraperitoneally (two injections, 1 h apart) and tissue 
potassium concentration was determined 2 h after the last injection. 








































































































Fig. 5 Effects of the administration of different doses of ornithine 
HCl to mice on plasma (a), pancreas (b) and liver (c) potassium levels. 
l‑Ornithine HCl was administered at the dose of 2, 3 or 4 g/kg (two 
injections, 1 h apart) and tissue potassium was determined 2 h after 
the last injection. Results are given as mean ± SE from six animals. 
Statistical significance: (*) P < 0.01, (**) P < 0.001, (***) P < 0.0001 
versus control
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et  al. 1967; Massara et  al. 1979). Similar increases have 
been reported in patients after the administration 
of l-arginine or l-lysine, used to prevent side effects 
induced by targeted radiolabelled peptide therapy in 
the treatment of neuroendocrine tumours (Barone et al. 
2004; Giovacchini et al. 2011). Moreover, whereas healthy 
individuals developed moderate hyperkalemia upon 
administration of arginine HCl, severe life-threatening 
hyperkalemia has been reported in patients with heart 
disease, renal failure or diabetes (Hertz and Richardson 
1972; Bushinsky and Gennari 1978; Massara et al. 1981).
Potassium is the most abundant intracellular cation in 
the human body and is required for vital cellular func-
tion. Serum potassium is tightly controlled through 
homeostatic mechanism and is affected by many factors 
(Young and McDonough 2009; Gumz et  al. 2015). The 
vast majority of total body potassium is located in the 
intracellular space. Even small changes in the distribu-
tion between intra and extracellular compartments can 
result in a marked rise in serum potassium (Dickerman 
and Walker 1964; Evans and Greenberg 2005). Differ-
ent authors have suggested that the increase in serum 
potassium after infusion of cationic amino acids to 
experimental animals or isolated tissues (Levinsky et  al. 
1962; Dickerman and Walker 1964) originates from the 
displacement of the intracellular potassium. Our results 
indicate that the three cationic amino acids used in the 
study produce similar effects on plasma potassium lev-
els. In addition, our data clearly demonstrate, for the first 
time, that the increase in plasma potassium produced 
by the administration of the dibasic amino acids is due 






























































Fig. 6 Effects of glucose administration on plasma, pancreas and 
liver potassium levels. d‑glucose (4 g/kg) was given intraperitoneally 
(two injections, 1 h apart) and tissue potassium concentration 
was determined 2 h after the last injection. Results are given as 
mean ± SE from six animals per group
Fig. 7 mRNA expression levels of cationic amino acid transporters 
(CAT1, CAT2A and CAT2B) in liver (a) and pancreas (b) of control and 
treated mice. l‑Ornithine HCl (4 g/kg) was given intraperitoneally 
(two injections, 1 h apart) and tissues were excised 2 h after the last 
injection, and RNA was extracted and analyzed by real‑time RT‑PCR. 
Results are given as relative expression to beta‑actin. Statistical signifi‑
cance: (*) P < 0.05 versus control of three animals per group
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the liver and pancreas to the extracellular compartments. 
This effect of the cationic amino acids on potassium lev-
els appears to be specific of these two tissues, since no 
significant decreases were observed in the heart, spleen, 
or testes. Interestingly, the administration of the cationic 
amino acids did not affect potassium levels in skeletal 
muscle, a tissue than in other situations appears to be 
important for regulating plasma potassium concentra-
tions (Gumz et al. 2015).
The unexpected increase in potassium brain levels, 
detected in our experiments after cationic amino acid 
administration, could be related with the reported effect 
of l-arginine administration on the release of growth hor-
mone (GH). It is generally accepted that insufficient sup-
ply of potassium is associated with growth retardation. 
Thus, in potassium deficient animals both basal GH lev-
els and GH response to GRF are reduced, this deficiency 
being corrected after potassium repletion (Flyvbjerg et al. 
1991; Gil-Peña et al. 2010). In addition, potassium infu-
sion to healthy man increases GH in plasma (Dluhy et al. 
1972), and increased serum potassium and GH release 
have been observed after infusion of cationic amino acids 
or after physical exercises (Merimee et  al. 1965; Hertz 
and Richardson 1972; Bushinsky and Gennari 1978; Mas-
sara et  al. 1979; Williams et  al. 1985; Bucci et  al. 1990; 
Chromiak and Antonio 2002; Kanaley 2008; Denura et al. 
2010).
It has been suggested that the changes in potassium 
homeostasis elicited by the cationic amino acids could 
be due to the effect of the chloride ions associated to the 
cationic amino acids, when they are administered under 
the hydrochloride form to improve solubility (Luiking 
and Deutz 2007). The results of the present study, show-
ing that the administration of ornithine aspartate to mice 
produced similar decrease in potassium levels in pan-
creas and liver than when ornithine was given under the 
hydrochloride form, makes unlikely the possibility that 
chloride could be the responsible of the decrease of the 
potassium content in these organs. However, the smaller 
increase in plasma potassium concentration observed, 
when ornithine aspartate was administered, suggests that 
chloride ions may exert a negative effect on renal potas-
sium secretion, and hence that the administration of the 
aspartate form of cationic amino acids could be safer 
than the one of chloride forms.
Our results also show that the effect of ornithine 
administration on potassium levels in plasma, pancreas 
and liver are dose dependent, suggesting that the uptake 
of the cationic amino acids by pancreas or liver is cou-
pled to the exit of potassium from these tissues. The lack 
of effect of DFMO administration on liver or pancreas 
potassium levels, in contrast to the effects observed for 
arginine, ornithine or lysine, also support the hypothesis 
that the exit of potassium is necessarily associated to the 
uptake of the cationic amino acid, since although DFMO 
is a dication, as ornithine and the other dibasic amino 
acids, it is poorly transported into the cells by the cati-
onic amino acid transporter (Erwin and Pegg 1982). In 
addition, the DFMO results also corroborate the lack of 
relevance of chloride ions on the potassium movements 
between pancreas or liver and plasma.
The capacity to drive potassium out of the cell is a 
property of all cationic amino acids and has been dem-
onstrated by in vitro (Levinsky et al. 1962) and in vivo 
experiments (Dickerman and Walker 1964). However, 
the molecular bases of this phenomenon are largely 
unknown. Cationic amino acids are transported through 
biological membranes by various distinct transport sys-
tems. The main family of cationic amino acid transport-
ers (CAT) comprises four members, CAT-1, CAT-2A, 
CAT-2B and CAT-3, which all exhibit a nearly identical 
substrate pattern for cationic amino acids (Palacin et al. 
1998; Hatzogluu et al. 2004; Closs et al. 2006). CAT-1is 
expressed in most tissues, except in the liver (Hatzogluu 
et al. 2004). In contrast, the two CAT-2 splice variants 
exhibit a much restricted expression pattern. CAT-2A 
is strongly expressed in the liver and to a lesser extent, 
in the pancreas, skeletal muscle, heart and vascular 
smooth muscle cells. CAT-2A serves to remove surplus 
cationic amino acid content (Palacin et  al. 1998; Closs 
et al. 2006). CAT-2B can be induced by pro-inflamma-
tory cytokines and bacterial polysaccharides in a variety 
of cell lines (Palacin et al. 1998; Closs et al. 2006). Our 
results in mice confirm that the liver express mainly 
CAT-2A and that the treatment with l-ornithine pro-
duce a significant increase of hepatic CAT-2A mRNA, 
with no effect on the expression of the other cationic 
amino acid transporters. We also found a small increase 
of CAT-2A and CAT-2B in pancreas after l-ornithine 
treatment. These last findings suggest that potassium 
drive out from liver and pancreas could be related with 
the high-capacity of CAT-2A to remove surplus cati-
onic amino acids. The molecular mechanisms by which 
cationic amino acid uptake is related with potassium 
exchange in pancreas and liver remains to be estab-
lished. Different studies conducted in Xenopus laevis 
oocytes expressing hCATs showed that hCAT-2A and 
hCAT-2B could also transport charged particles other 
than cationic amino acids and that potassium can easily 
pass using the transporter in absence of arginine (Naw-
rath et al. 2000; Rotmann et al. 2004). From the results 
of the present study is not possible to know if after the 
treatment with higher doses of cationic amino acids, 
potassium leaks the liver and pancreas only through 
CATs transporters or requires an associated channel for 
driving potassium out of the cell.
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It could be argued that the observed effects of the basic 
amino acids on potassium exit from liver or pancreas could 
be related to the formation of different products derived 
from the catabolism of the basic amino acids. However, 
whereas arginine catabolism leads to the production of 
several compounds, including NO, ornithine, guanidine 
acetate, etc., the catabolism of lysine produces different 
compounds (Wu et al. 2009; Wu 2013). Our results, showing 
that lysine and ornithine caused the same effect on potas-
sium levels than arginine, do not support this possibility.
There are numerous animal studies in which the acute 
administration of large doses of l-arginine has been used 
as an experimental model for acute pancreatitis (Tani 
et  al. 1990; Takács et  al. 2002; Hegyi et  al. 2004; Dawra 
et al. 2006; Hyvönen et al. 2006; Kang et al. 2014). How-
ever, potential changes in potassium homeostasis were 
not analyzed. There are also nutritional studies where 
long term dietary supplementation of l-arginine up to 
3.6  g/kg body weight/day in the drinking water during 
13  weeks did not show adverse effects in rats, although 
no data on potassium changes were available (Yang et al. 
2015). In pigs, fed with supplementation of arginine (up 
to 630  mg  l-arginine/kg/day for 91  days), potassium 
plasma levels did not change (Hu et al. 2015), although in 
this study the pancreas and liver levels of potassium were 
not determined. In this regard, it should be noted that in 
our present study we found that ornithine, at the dose 
of 2  g/kg body weight, induced a significant decrease 
of pancreas and liver potassium levels with no change 
in plasma levels. It is then conceivable that the altera-
tion of potassium levels may be dependent on the rate 
of basic amino acid increase in plasma. In the last dec-
ades, the use of amino acids such as l-arginine, l-lysine 
or l-ornithine by many athletes, in order to rise growth 
hormone, has notably increased (Isidori et al. 1981; Bucci 
et  al. 1990; Chromiak and Antonio 2002; Denura et  al. 
2010). In some cases, acute pancreatitis was observed 
as another hazardous effect of l-arginine supplementa-
tion (Saka et al. 2004).The possible implication of potas-
sium changes in the pancreatic alterations observed 
after cationic amino acid supplementation has not been 
explored. However, several authors have demonstrated 
an association between dietary potassium and diabe-
tes risk (Heianza et al. 2011; Chatterjee et al. 2012). The 
mechanism through which dietary potassium may affect 
glucose metabolism and diabetes risk is not well known, 
but several studies have evaluated that potassium deple-
tion resulting from thiazide treatment may be the media-
tor of this increased risk (Zillich et  al. 2006; Shafi et  al. 
2008). In fact, it is well documented the role of potas-
sium for maintaining the normal secretory activity of 
β-cells (Bergsten et  al. 1986). Furthermore, infusion of 
potassium either in man or in animals stimulates insulin 
secretion (Dluhy et al. 1972, Hiatt et al. 1972). Other fac-
tor associated with an increased risk of type2 diabetes 
is a high protein diet (Aune et al. 2009; Pan et al. 2011; 
Ericson et al. 2013). In this regard, it has been reported 
that the replacement of dietary protein by carbohydrates 
is related with a decrease in the risk of type 2 diabetes 
(Schulze et al. 2008). Our data reveals that the overload 
of glucose does not affect pancreatic potassium levels. 
Little is known about the reasons for the association 
between dietary proteins and type 2 diabetes. Accord-
ing to our results, one may speculate that the alteration 
of pancreatic potassium levels observed after admin-
istration of high amount of cationic amino acids, might 
result, after all, in abnormal insulin secretion. The effects 
of long term consumption of high protein diets on diabe-
tes development are unknown, but the increased preva-
lence of type 2 diabetes in developing countries could be 
related with the increased intake of proteins in the diet.
In conclusion, our results demonstrate that hyper-
kalemia associated to high intake of cationic amino acids 
is related to the specific potassium depletion in liver and 
pancreas, and suggest that the expression of CAT-2A in 
these tissues may favor the interchange of potassium by 
cationic amino acids in these organs.
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